慢性乙型肝炎病毒基因型与干扰素治疗应答的关系

HBV genotypes and efficacy of interferon-α on patients with chronic hepatitis B.

观察慢性乙型肝炎病毒基因型与α -干扰素治疗慢性乙型肝炎患者疗效的关系。利用限制性片段长度多态性分析技术 ,由限制性内切酶AvaⅡ和DpnⅡ作用于前S区扩增片段建立的简便的HBV基因型分型方法 ,对 6 0例经干扰素治疗的慢性乙型肝炎患者的血清HBV进行基因型测定 ,显示B基因型 31例 (5 1 7% ) ,C基因型 2 6(43 3% ) ,D基因型 3例 (5 0 % )。B型、C型与干扰素应答无明显差异 (P >0 0 5 ) ,3例D型均有效。由于我国大部分地区HBV基因型以B型和C型为主 ,HBV基因型可能不是预测干扰素疗效的重要因素。D型对干扰素应答率高 ,有待进一步研究。

To observe the relationship between HBV genotypes of chronic hepatitis B and efficacy of interferon-α therapy. A simplified RFLP method was established with AvaⅡ and DpnⅡ at amplified segment of the pre-S of HBV DNA. The method was applied to 60 serum samples from patients with chronic hepatitis B on IFN-α therapy. The genotype B was detected in 51 7%(31/60). The difference was not significant in responsive rate to IFN-α therapy between genotype B and genotype C ( P >0 05). Three patients of genotype D are effective on therapy. The Genotypes B and Genoltypes C are prevalent in a majority of area in our country. HBV genotypes might not be an important predictive factor in determining the efficacy of IFN-α therapy. The study indicates Genotype D is higher in responsive rate to IFN-α therapy.